Automate Your Wheel Strategy on SYK
With Tiblio's Option Bot, you can configure your own wheel strategy including SYK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SYK
- Rev/Share 62.3182
- Book/Share 55.4448
- PB 6.9408
- Debt/Equity 0.8083
- CurrentRatio 1.7842
- ROIC 0.1151
- MktCap 147123202810.0
- FreeCF/Share 9.359
- PFCF 41.1303
- PE 50.4051
- Debt/Assets 0.3697
- DivYield 0.0086
- ROE 0.1408
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | SYK | Citigroup | -- | Buy | -- | $450 | Feb. 26, 2025 |
| Initiation | SYK | Wolfe Research | -- | Outperform | -- | $405 | Sept. 10, 2024 |
News
Stryker Q2: Record Mako Installation And High Utilization
Published: August 19, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate a Hold rating on Stryker Corporation, with a fair value of $382 per share, despite recent strong quarterly results. Stryker's Mako installations and utilization remain robust, and upcoming Mako Spine and shoulder launches are on track to drive future growth. SYK management is focused on margin expansion through supply chain efficiencies, but cost synergies from past acquisitions remain under-realized.
Read More
Stryker: Strong Multi-Faceted Growth Continuing To Support The Shares
Published: August 19, 2025 by: Seeking Alpha
Sentiment: Positive
Stryker continues to outperform peers with strong revenue growth, margin expansion, and successful product innovation. Recent quarterly results beat expectations, driven by robust performance across the business and ongoing market share gains. Management remains focused on growth and margin optimization, with M&A and innovation — especially in robotics and neuromodulation — central to the strategy.
Read More
Stryker (SYK) Upgraded to Buy: What Does It Mean for the Stock?
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Stryker (SYK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
SNN vs. SYK: Which Stock Is the Better Value Option?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
Read More
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RL, SYK, RGLD and ADSK hold promise.
Read More
Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital
Published: August 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain disorders, today announces the appointment of Tim Scannell, former President & COO of Stryker Corporation, as Chair of its Board of Directors. The company also reveals a $10 million strategic capital partnership with Soleus Capital to accelerate hiring, product development, and medical education efforts in the United States and abroad.
Read More
Are Medical Stocks Lagging Stryker (SYK) This Year?
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Stryker (SYK) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
Read More
Stryker (SYK) Reports Q2 Earnings: What Key Metrics Have to Say
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
SYK Stock Falls Despite Q2 Earnings & Sales Beat, '25 View Up
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Negative
SYK's second-quarter results reflect strong segmental performance, along with a rise in operating margin.
Read More
Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang?
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Stryker's second-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs and tariffs are likely to have continued to hurt margins.
Read More
SNN or SYK: Which Is the Better Value Stock Right Now?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Smart Money Going in Senior Health: Key Stocks in Elderly Care
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Read More
HLN vs. SYK: Which Stock Is the Better Value Option?
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Products stocks are likely familiar with Haleon PLC Sponsored ADR (HLN) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.
Read More
The 3 Most Overvalued Stocks Top Managers Are Selling in 2025
Published: June 03, 2025 by: Morningstar
Sentiment: Negative
The best fund managers are scaling back in these expensive stocks this year. 00:00 Introduction 00:39 Netflix NFLX 01:23 Mastercard MA 02:07 Stryker SYK Susan Dziubinski: I'm Susan Dziubinski with Morningstar.
Read More
PBH vs. SYK: Which Stock Is the Better Value Option?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
Read More
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
Read More
Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich.
Read More
Final Trades: Rockwell Automation, Alerian MLP, Lockheed Martin and Stryker
Published: May 05, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee kick off the week with their top picks. Don't miss it!
Read More
SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Negative
SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.
Read More
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.
Read More
Strong Segmental Performance to Drive Stryker's Q1 Earnings?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Negative
SYK's first-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Read More
PBH vs. SYK: Which Stock Is the Better Value Option?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Stryker Corporation (SYK) Citi's 2025 Unplugged Medtech and Life Sciences Access Day (Transcript)
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Stryker Corporation (NYSE:SYK ) Citi's 2025 Unplugged Medtech and Life Sciences Access Day February 27, 2025 12:15 PM ET Company Participants Preston Wells - CFO Jason Beach - VP, Finance, IR Conference Call Participants Joanne Wuensch - Citigroup Joanne Wuensch Joanne Wuensch, the medical technology analyst here at Citi Bank. So for our next session, I'm quite thrilled to have the incoming CFO, Preston Wells and Jason Beach, which I think people know quite well.
Read More
PAHC or SYK: Which Is the Better Value Stock Right Now?
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
SYK Trades Below 52-Week High: Should You Buy, Hold or Sell the Stock?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Stryker is gaining momentum with strong Q4 results, innovative medtech solutions and high-growth market expansion. But, is the stock still a buy?
Read More
Stryker to participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Portage, Michigan, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day on Thursday, February 27, 2025 at Citigroup Headquarters, New York, New York.
Read More
About Stryker Corporation (SYK)
- IPO Date 1980-03-17
- Website https://www.stryker.com
- Industry Medical - Devices
- CEO Kevin A. Lobo
- Employees 53000